Search Results 851-860 of 17102 for monoclonal antibody

1. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[D-VTd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[D-VRd\]), or ...

2. Dasatinib And Quercetin With CAR T Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody (mAb) * Ciltacabtagene autoleucel (Carvykti) available ... * Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, ...

3. Primary immunodeficiency - Symptoms & causes - Mayo Clinic

   They can be broadly classified into six groups based on the part of the immune system that's affected: B cell (antibody) deficiencies. T cell deficiencies.

4. A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

   Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E (IgE) therapy ...

5. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

   2 cycles of an anti-CD20 monoclonal antibody (unless investigator determines that tumor is CD20 negative) and anthracycline-containing regimen (e.g., DA ...

6. Ulcerative colitis - Diagnosis and treatment - Mayo Clinic

   Kaplan GG. Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Related.

7. Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma - Mayo Clinic

   Participation eligibility · Received any prior monoclonal antibody against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1); ...

8. Herd immunity, antibodies & COVID-19 / bile duct cancer / peripheral artery disease - Mayo Clinic News Network

   Herd immunity, antibodies & COVID-19 / bile duct cancer / peripheral artery disease. Aug. 1, 2020. Related Episodes.

9. Open-label Trial of Daratumumab in Treatment of PGNIMD and C3 GN - Mayo Clinic

   ... monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to ...

10. A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients - Mayo Clinic

    Receipt of ≥ 2 prior lines of therapy and progressed on treatment with an anti-CD38 monoclonal antibody (Cohort D3). Receipt of ≥ 4 lines of prior therapy ...